Related Experiment Videos
Cholesterol: precursor to many lipid disorders
Insights
Lowering low-density lipoprotein cholesterol (LDL-C) significantly reduces coronary heart disease (CHD) risk. Aggressive LDL-C reduction in at-risk patients, identified by risk scores, offers greater CHD event reduction and improved outcomes.
Area of Science:
- Cardiovascular Medicine
- Public Health
- Clinical Lipidology
Background:
- Coronary heart disease (CHD) is the leading cause of death in the US, with elevated low-density lipoprotein cholesterol (LDL-C) as a major risk factor.
- National Cholesterol Education Program guidelines (ATP II and ATP III) have evolved to identify more patients eligible for lipid-lowering therapy.
- Despite guideline updates, many eligible patients are not receiving treatment, and fewer than half achieve their LDL-C goals.
Purpose of the Study:
- To emphasize the critical need for lowering LDL-C to reduce coronary heart disease (CHD) risk.
- To highlight the benefits of aggressive LDL-C reduction in at-risk populations.
- To underscore the importance of identifying at-risk patients and ensuring treatment adherence.
Main Methods:
- Review of randomized clinical trials and large-scale prevention trials evaluating lipid-lowering therapies, primarily statins.
- Analysis of guideline recommendations from the Adult Treatment Panel (ATP) II and ATP III for CHD risk assessment and management.
- Examination of treatment goal achievement rates among patients on lipid-lowering therapy.
Main Results:
- Lowering LDL-C demonstrably reduces the risk of fatal and nonfatal coronary events.
- More aggressive LDL-C reductions yield greater CHD risk reduction, particularly in high-risk individuals.
- The benefits of lipid-lowering therapy are more pronounced in patients with higher baseline CHD risk.
Conclusions:
- Aggressive LDL-C reduction is crucial for mitigating coronary heart disease (CHD) risk.
- Targeting at-risk patients identified through risk prediction scoring systems is essential for maximizing therapeutic benefits.
- Effective CHD risk management requires appropriate treatment implementation and ensuring patient compliance with lipid-lowering therapy.
Abstract:
Despite advances in treatment and prevention, coronary heart disease (CHD) remains the leading cause of death in the United States. A major risk factor for CHD is elevated low-density lipoprotein cholesterol (LDL-C). Randomized clinical trials have proven that lowering LDL-C to near target levels significantly reduces CHD risk. More aggressive LDL-C reductions would have an even greater impact on reducing CHD risk if these goal levels were applied to all patients at risk, as identified by a CHD risk prediction scoring system. In 1993 the second Adult Treatment Panel (ATP II) of the National Cholesterol Education Program issued guidelines that defined CHD risk on the basis of whether a patient qualified for primary or secondary prevention. The ATP III guidelines, issued May 2001, introduce the concept of CHD-equivalent risk in patients without known CHD, thereby expanding considerably the number of people eligible for lipid-lowering therapy. Unfortunately, many patients who are eligible for therapy are not receiving it, and among those on lipid-lowering therapy, less than half have achieved their treatment goals. As mentioned, findings from several large-scale primary- and secondary-prevention trials with statins and other lipid-lowering agents have shown that lowering LDL-C reduces the risk for fatal and nonfatal coronary events and results in fewer hospitalizations and revascularization procedures. In fact, a review of the 5 major statin trials reveals that the higher the patient's baseline CHD risk, the more striking the benefits of therapy are. Clearly, the need to lower LDL-C levels is crucial. Meeting this need involves targeting patients who are at risk, implementing appropriate treatment, and ensuring compliance with therapy.